Ravi K Amaravadi, MD

faculty photo
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member, Abramson Cancer Center
Member, Institute of Translational Medicine and Therapeutics
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
co-Leader , Cancer Therapeutics Program, Abramson Cancer Center
Co-Director, University of Pennsylvania/Wistar Institute SPORE in Skin Cancer
Associate Director, Translational Research, Abramson Cancer Center
Department: Medicine
Graduate Group Affiliations

Contact information
Division of Hematology Oncology
8 BRB - Room 852
Philadelphia, PA 19104
Office: 215-769-5159
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Description of Clinical Expertise

Phase I and Phase II Clinical Trials

Selected Publications

Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W.: Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep 42: 113224, Oct 2023.

Aggarwal C, Maity AP, Bauml JM, Long Q, Aleman T, Ciunci C, D'Avella C, Volpe M, Anderson E, Jones LM, Sun L, Singh AP, Marmarelis ME, Cohen RB, Langer CJ, Amaravadi R.: A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Oncologist 28: 644-e564, Jul 2023.

Hong H, Friedland A, Hu M, Anstrom KJ, Halabi S, McKinnon JE, Amaravadi R, Rojas-Serrano J, Abella BS, Portillo-Vázquez AM, Woods CW, Hernandez AF, Boulware DR, Naggie S, Rajasingham R.: Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open 13: e065305, Jun 2023.

Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, Mitchell TC.: Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Res Commun 3: 821-829, May 2023.

Jain V, Singh MP, Amaravadi RK.: Recent advances in targeting autophagy in cancer. Trends Pharmacol Sci Mar 2023.

Bhardwaj M, Lee JJ, Versace AM, Harper SL, Goldman AR, Crissey MAS, Jain V, Singh MP, Vernon M, Aplin AE, Lee S, Morita M, Winkler JD, Liu Q, Speicher DW, Amaravadi RK.: Lysosomal lipid peroxidation regulates tumor immunity. J Clin Invest Feb 2023.

Jain V, Harper SL, Versace AM, Fingerman D, Brown GS, Bhardwaj M, Crissey MAS, Goldman AR, Ruthel G, Liu Q, Zivkovic A, Stark H, Herlyn M, Gimotty PA, Speicher DW, Amaravadi RK.: Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. Cancer Discov 13: 454-473, Feb 2023.

Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, Luo R, Elder DE, Huang AC, Karakousis G, Miura J, Mitchell T, Schuchter L, Amaravadi R, Flowers A, Mou H, Yi F, Guo W, Ko J, Chen Q, Tian B, Herlyn M, Xu X.: Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine 2023.

Tcyganov EN, Sanseviero E, Marvel D, Beer T, Tang HY, Hembach P, Speicher DW, Zhang Q, Donthireddy LR, Mostafa A, Tsyganova S, Pisarev V, Laufer T, Ignatov D, Ferrone S, Meyer C, Maby-El Hajjami H, Speiser DE, Altiok S, Antonia S, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Yuan Z, Montaner LJ, Celis E, Gabrilovich DI.: Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy. Cancer Cell 40: 1173-1189, Oct 2022.

Guan L, Wu B, Li T, Beer LA, Sharma G, Li M, Lee CN, Liu S, Yang C, Huang L, Frederick DT, Boland GM, Shao G, Svitkina TM, Cai KQ, Chen F, Dong MQ, Mills GB, Schuchter LM, Karakousis GC, Mitchell TC, Flaherty KT, Speicher DW, Chen YH, Herlyn M, Amaravadi RK, Xu X, Guo W.: HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8(+) T-cell infiltration into tumors. Nat Commun 13: 4078, Jul 2022.

back to top
Last updated: 11/01/2023
The Trustees of the University of Pennsylvania